Titanovo Logo
Back to Cell Types

ES-2Homo sapiens (Human)Cancer cell line

Also known as: ES2

🤖 AI SummaryBased on 13 publications

Quick Overview

Human ovarian cancer cell line with unique molecular features.

Detailed Summary

ES-2 is a human ovarian cancer cell line derived from a poorly differentiated clear cell carcinoma. It has been extensively studied for its genetic and molecular characteristics, including mutations in key oncogenes and tumor suppressor genes. Research has highlighted its distinct features compared to other ovarian cancer cell lines, particularly in terms of histological and genetic profiles. ES-2 is notable for its lack of TP53 mutations, which is a common feature in many ovarian cancers, and its unique expression patterns of biomarkers such as HNF-1B and WT1. These characteristics make ES-2 a valuable model for studying the molecular mechanisms of ovarian clear cell carcinoma and for evaluating therapeutic strategies.

Research Applications

Molecular mechanisms of ovarian clear cell carcinomaGenetic and epigenetic alterations in cancerTherapeutic target identificationDrug sensitivity and resistance studies

Key Characteristics

Lack of TP53 mutationsUnique expression of HNF-1B and WT1Distinct genetic profile compared to other ovarian cancer cell lines
Generated on 6/20/2025

Basic Information

Database IDCVCL_3509
SpeciesHomo sapiens (Human)
Tissue SourceOvary[UBERON:UBERON_0000992]

Donor Information

Age47
Age CategoryAdult
SexFemale
Raceblack_or_african_american

Disease Information

DiseaseClear cell adenocarcinoma of the ovary
LineageOvary/Fallopian Tube
SubtypeClear Cell Ovarian Cancer
OncoTree CodeCCOV

DepMap Information

Source TypeATCC
Source IDACH-000906_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Ser241Phe (c.722C>T)Unspecified-PubMed=23851445, PubMed=17260012
MutationSimpleTERTc.242_243CC>TT (-138/-139CC>TT)UnspecifiedIn promoterPubMed=23348503
MutationSimplePALB2p.Lys295_Met296insTer (c.886delA) (p.Met296Terfs)Unspecified-from parent cell line ES-2
MutationSimpleBRAFp.Val600Glu (c.1799T>A)Unspecified-PubMed=26214590

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10,15
D10S1248
14,16
D12S391
20,21
D13S317
11
D16S539
11,13
D18S51
13,15
D19S433
15,15.2
D1S1656
13,16
D21S11
32.2
D22S1045
14,16
D2S1338
17,23
D2S441
11
D3S1358
15,18
D5S818
11,13
D7S820
11
D8S1179
14
FGA
21
Penta D
8,13
Penta E
13,16
TH01
9.3
TPOX
8,12
vWA
16,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

DOIPubMed

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.

Velculescu V.E., Scharpf R.B.

Cell Rep. 25:2617-2633(2018).

DOIPubMedPMC

Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.

Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.

Cell Rep. 18:2343-2358(2017).

DOIPubMed

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

Kinome-wide decoding of network-attacking mutations rewiring cancer signaling.

Itamochi H., Bodenmiller B., Erler J.T., Turk B.E., Linding R.

Cell 163:202-217(2015).

DOIPubMedPMC

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

OncoImmunology 3:e954893.1-e954893.12(2014).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

Helleman J.

PLoS ONE 9:E103988-E103988(2014).

DOIPubMedPMC

Caution over use of ES2 as a model of ovarian clear cell carcinoma.";

Cheung A.N.-Y.

J. Clin. Pathol. 67:921-922(2014).

DOIPubMed

Type-specific cell line models for type-specific ovarian cancer research.

Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.

PLoS ONE 8:E72162-E72162(2013).

DOIPubMedPMC

Evaluating cell lines as tumour models by comparison of genomic profiles.

Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.

Nat. Commun. 4:2126.1-2126.10(2013).

DOIPubMedPMC

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

Mills G.B., Hennessy B.T.

Mol. Oncol. 7:567-579(2013).

DOIPubMedPMC

DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.

Lessey B.A., Jordan V.C., Bradford A.P.

Gynecol. Oncol. 127:241-248(2012).

DOIPubMedPMC

Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.

Miyazaki K.

Hum. Pathol. 43:2197-2206(2012).

DOIPubMed

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Genomic complexity and AKT dependence in serous ovarian cancer.";

Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.

Cancer Discov. 2:56-67(2012).

DOIPubMedPMC

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOIPubMedPMC

Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.

Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.

Oncol. Rep. 23:1021-1026(2010).

DOIPubMedPMC

A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.";

Anderson M.L., Matzuk M.M.

Mol. Endocrinol. 24:447-463(2010).

DOIPubMedPMC

Enhancement of gene expression efficiency using cationic liposomes on ovarian cancer cells.

Serikawa T., Kikuchi H., Oite T., Tanaka K.

Drug Deliv. 15:523-529(2008).

DOIPubMed

Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains.

Knudsen B.S., Hanash S.M.

PLoS ONE 3:E2425-E2425(2008).

DOIPubMedPMC

Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.

Hirohashi S., Inazawa J., Imoto I.

Cancer Res. 67:7095-7105(2007).

DOIPubMed

Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines.

Chen X., Sikic B.I.

Genes Chromosomes Cancer 45:365-374(2006).

DOIPubMed

Gene expression patterns in ovarian carcinomas.";

Sikic B.I.

Mol. Biol. Cell 14:4376-4386(2003).

DOIPubMedPMC

Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer.

Rosenshein N.B., Cho K.R., Riggins G.J., Morin P.J.

Cancer Res. 60:6281-6287(2000).

PubMed

Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.

Berchuck A., Futreal P.A.

Gynecol. Oncol. 70:13-16(1998).

DOIPubMed

Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.

Lau D.H.M., Lewis A.D., Ehsan M.N., Sikic B.I.

Cancer Res. 51:5181-5187(1991).

PubMed

ES-2 ovarian cancer cells present a genomic profile inconsistent with their reported history.

Devor E.J., Lapierre J.R., Bender D.P.

Obstet. Gynecol. Res. 4:233-238(2021).

DOI

Web Resources

thermofisher.comtcpaportal.org